PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33085775-10 2021 Moreover, after using the autophagy activator rapamycin, the expression of the inflammatory cytokines interleukin-1beta was decreased and the pain symptoms were alleviated. Sirolimus 46-55 interleukin 1 beta Mus musculus 102-119 34065421-8 2021 Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated. Sirolimus 108-117 interleukin 1 beta Mus musculus 189-193 33010263-9 2020 Finally, rapamycin-mediated promotion of autophagy attenuated LPS-induced anxiety-like behavior and decreased interleukin-1beta and Iba-1 expression in the hippocampus. Sirolimus 9-18 interleukin 1 beta Mus musculus 110-127 32421368-12 2020 We found that mTORC1 inhibition with low doses of rapamycin (2, 20 nM) lowered macrophage priming of IL-1b mRNA and secretion of IL-1b caused by multiple statins. Sirolimus 50-59 interleukin 1 beta Mus musculus 101-106 32421368-12 2020 We found that mTORC1 inhibition with low doses of rapamycin (2, 20 nM) lowered macrophage priming of IL-1b mRNA and secretion of IL-1b caused by multiple statins. Sirolimus 50-59 interleukin 1 beta Mus musculus 129-134 31803045-10 2019 Melatonin and rapamycin significantly ameliorated the isoflurane-induced cognitive impairment and also led to a decrease in the melatonin levels as well as the expression levels of TNF-alpha, IL-1beta, IL-6, and p-mTOR in the hippocampus. Sirolimus 14-23 interleukin 1 beta Mus musculus 192-200 30557824-0 2019 Rapamycin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting IL-1beta and IL-18 production. Sirolimus 0-9 interleukin 1 beta Mus musculus 81-89 31174699-4 2019 Here, results showed that pretreatment with rapamycin reduced the pyroptosis of peritoneal macrophages stimulated by cecal contents and the release of inflammatory factors such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha); In septic mice, rapamycin treatment decreased the activation of inflammasome in lung, and alleviated the pathological injuries in lung, liver and spleen tissues during acute stage of sepsis. Sirolimus 44-53 interleukin 1 beta Mus musculus 180-197 31174699-4 2019 Here, results showed that pretreatment with rapamycin reduced the pyroptosis of peritoneal macrophages stimulated by cecal contents and the release of inflammatory factors such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha); In septic mice, rapamycin treatment decreased the activation of inflammasome in lung, and alleviated the pathological injuries in lung, liver and spleen tissues during acute stage of sepsis. Sirolimus 44-53 interleukin 1 beta Mus musculus 199-207 30557824-2 2019 However, it is not clear whether the mTOR specific inhibitor rapamycin can attenuate lipopolysaccharide (LPS)-induced ALI by modulating IL-1beta and IL-18 production. Sirolimus 61-70 interleukin 1 beta Mus musculus 136-144 30557824-3 2019 In this study, we found that rapamycin ameliorated LPS-induced ALI by inhibiting NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated IL-1beta and IL-18 secretion. Sirolimus 29-38 interleukin 1 beta Mus musculus 162-170 29862167-6 2018 RESULTS: In C57BL/6 mice, rapamycin treatment decreased the clinical scores and production of the pro-inflammatory cytokine, IL-1beta. Sirolimus 26-35 interleukin 1 beta Mus musculus 125-133 28333137-7 2017 In addition, the expression of pro-inflammatory cytokines IL-1beta and IFN-gamma mRNA was downregulated while the expression of TGF-beta1 and Foxp3 mRNA was upregulated in kidney tissue after transferring rapamycin-treated MDSCs. Sirolimus 205-214 interleukin 1 beta Mus musculus 58-66 28333137-8 2017 Adoptive transfer of rapamycin-treated MDSCs also downregulated the serum levels of IL-1beta, IL-6 and IFN-gamma and upregulated the serum levels of TGF-beta1 compared with the IR group and PBS-treated MDSC group. Sirolimus 21-30 interleukin 1 beta Mus musculus 84-92 22212527-0 2012 Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Sirolimus 9-18 interleukin 1 beta Mus musculus 91-99 22084394-10 2012 Rapamycin treatment also maintained cartilage cellularity and decreased ADAMTS-5 and interleukin-1beta expression in articular cartilage. Sirolimus 0-9 interleukin 1 beta Mus musculus 85-102 27663762-10 2016 Rapamycin treatment attenuated interleukin 1beta and transforming growth factor beta induction in irradiated lungs compared with the control diet. Sirolimus 0-9 interleukin 1 beta Mus musculus 31-84 26481278-14 2016 Rapamycin treatment inhibited interleukin-1beta, 6, 13, and 17 on days 7 and 14. Sirolimus 0-9 interleukin 1 beta Mus musculus 30-47 26517816-10 2015 In ex-vivo study, LPS induced prominent production of IL-1beta and MCP-1 in cultured RAW264.7 cells, which was significantly suppressed by rapamycin. Sirolimus 139-148 interleukin 1 beta Mus musculus 54-62 21200439-7 2010 We found that mTORC1-S6K suppression by rapamycin delayed mortality of mice challenged with lethal endotoxin, and was associated with dampened circulating levels of VEGF, IL-1beta, IFN-gamma and IL-5. Sirolimus 40-49 interleukin 1 beta Mus musculus 171-179 21228274-4 2011 After treatment of macrophages with Toll-like receptor ligands, pro-IL-1beta was specifically sequestered into autophagosomes, whereas further activation of autophagy with rapamycin induced the degradation of pro-IL-1beta and blocked secretion of the mature cytokine. Sirolimus 172-181 interleukin 1 beta Mus musculus 213-221 21228274-7 2011 Induction of autophagy in mice in vivo with rapamycin reduced serum levels of IL-1beta in response to challenge with LPS. Sirolimus 44-53 interleukin 1 beta Mus musculus 78-86 20086156-3 2010 Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation. Sirolimus 54-63 interleukin 1 beta Mus musculus 139-156 20086156-3 2010 Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation. Sirolimus 54-63 interleukin 1 beta Mus musculus 158-166 18566370-3 2008 We report that in vitro and in vivo conditioning of murine myeloid DC with RAPA elicits the de novo production of IL-1beta by otherwise phenotypically immature DC. Sirolimus 75-79 interleukin 1 beta Mus musculus 114-122 16174862-7 2006 Blockade of the phosphoinositide 3-kinase pathway with LY-294002 or the p70s6-kinase pathway with rapamycin in the presence of TSA and IL-1beta inhibited 389Thr phosphorylation of p70s6 kinase, promoted binding of acetylated histone H4 to the iNOS promoter, and further suppressed iNOS protein expression and iNOS promoter activity. Sirolimus 98-107 interleukin 1 beta Mus musculus 135-143